Search

To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics., Competing Interests: OUD and BA are the employees of Pfizer Biopharmaceuticals Group, Istanbul, Türkiye. BOU reports research support for clinical trials through institution from Novartis, GSK, Astra Zeneca; honoraria from BMS, Amgen, Novartis, Pfizer, Astra Zeneca, Roche, MSD; support for attending meetings from Roche, Pfizer, Novartis and is on the advisory boards of Takeda, Roche, Astra Zeneca, MSD, Novartis, Amgen, Gilead. ME has support funding for medical writing from Pfizer, provides lectures for Pfizer, Novartis, Roche, Astellas, Janssen, MSD, Gen, Nobel, Deva, Eczacibasi, BMS, Takeda, Astra Zeneca, has support for attending meetings from Roche, has participation on advisory board of Novartis, Pfizer, Roche, Astellas, MSD, Deva, Astra Zeneca. The remaining authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

The ionizing radiation used during endoscopic retrograde cholangiopancreatography (ERCP) can have harmful effects on patients and staff. The aim of the study was to determine the effect of radiation on nurses working in an ERCP unit. A descriptive, cross-sectional study was completed between June and August 2022 with the voluntary participation of 114 ERCP nurses. The data were collected using WhatsApp messenger through a Google Form. It was determined that, of the nurses, 68.4% received training on radiation safety, all of them took protective measures, 98.2% had knowledge about the effects of radiation, and 93.9% used dosimeters. Nurses stated that they mostly experienced fatigue (94.7%), loss of energy (68.4%), headache (39.3%), hair loss (35.1%), weakness (18%), leg and joint pain (15.1%), thyroid diseases (12.3%), skin discoloration (7.9%), and anemia (7.9%) as the possible effects of radiation during the period they worked in ERCP. The study found that 3.5% of the nurses were diagnosed with cancer while working in the endoscopic retrograde cholangiopancreatography unit. Additionally, ERCP nurses experienced the negative effects of radiation at different rates, but there was no significant relationship between demographic and health characteristics and experiencing the negative effects of radiation., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2024 Society of Gastroenterology Nurses and Associates.)

The fear of death associated with cancer and the side effects of its treatments can have a detrimental psychological impact on breast cancer patients. Early detection and support services play a crucial role in alleviating the expected symptoms of depression, anxiety, and sexual dysfunction. The objective of our study is to assess the levels of depression, anxiety, and sexual dysfunction in breast cancer patients, as well as identify the factors that influence these conditions. The study involved 329 voluntarily participating breast cancer patients who had undergone surgery and were in the follow-up stage. Data were collected from 8 different centers after obtaining ethical approval. The assessment utilized tools such as the Sociodemographic Information Form, Beck Depression and Anxiety Scale, and Arizona Sexual Experiences Scale. Data analysis was performed using SPSS 20. The study included 329 breast cancer patients in the follow-up stage post-surgery. Their average age was 52.7 years (range: 27-83). Results indicated that 33.1% experienced moderate to severe depression, 18.2% reported severe anxiety, and 82.7% scored above 11 on the sexual scale. Factors linked to higher scores were mastectomy, surgical dissatisfaction, insufficient information on sexual side effects, and comorbidities like smoking and diabetes. The study emphasizes the importance of closely monitoring anxiety, depression levels, and sexual side effects in breast cancer treatment. It underscores the need to focus not only on reducing mortality rates but also on supporting patients' psychological and sexual well-being, ultimately improving their overall quality of life., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)

The aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65 patients treated with Atez/Bev for advanced HCC from 22 institutions in Turkey between September 2020 and March 2023. Responses were evaluated by RECIST v1.1 criteria. The median progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Cox regression model was employed to conduct multivariate analyses. The median age was 65 (range, 22-89) years, and 83.1% of the patients were male. A total of 1.5% achieved a complete response, 35.4% had a partial response, 36.9% had stable disease, and 26.2% had progressive disease. The disease control rate was 73.8% and associated with alpha-fetoprotein levels at diagnosis and concomitant antibiotic use. The incidence rates of any grade and grade ≥ 3 adverse events were 29.2% and 10.7%, respectively. At a median follow-up of 11.3 (3.4-33.3) months, the median PFS and OS were 5.1 (95% CI: 3-7.3) and 18.1 (95% CI: 6.2-29.9) months, respectively. In univariate analyses, ECOG-PS ≥ 1 (relative to 0), Child-Pugh class B (relative to A), neutrophil-to-lymphocyte ratio (NLR) > 2.9 (relative to ≤ 2.9), and concomitant antibiotic use significantly increased the overall risk of mortality. Multivariate analysis revealed that ECOG-PS ≥ 1 (HR: 2.69, P = .02), NLR > 2.9 (HR: 2.94, P = .017), and concomitant antibiotic use (HR: 4.18, P = .003) were independent predictors of OS. Atez/Bev is an effective and safe first-line therapy for advanced-stage HCC in a real-world setting. The survival benefit was especially promising in patients with a ECOG-PS score of 0, Child-Pugh class A, lower NLR, and patients who were not exposed to antibiotics during the treatment., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)

Purpose of Review: The aim of this narrative review is to evaluate the current available literature on urinary outcomes following cryotherapy and high-intensity focused ultrasound (HIFU) for localized prostate cancer (PCa)., Recent Findings: The available literature is heterogeneous in terms of intervention modalities and assessment of urinary outcome measures. Nevertheless, ultra-minimally invasive treatments seem to provide good urinary outcomes. Technological advancement and the adoption of more conservative ablation templates allow for a further reduction of toxicity and better preservation of urinary function. Urinary incontinence occurs in 0-10% of the patients and, is mostly transient. Voiding and storage lower urinary tract symptoms (LUTS) mostly occur in the early postoperative period and rarely require surgical treatment. Focal therapies performed with a salvage intent after external beam radiotherapy have a significantly higher impact on patient's urinary function., Summary: Ultra-minimally invasive treatment for PCa show a good safety profile concerning urinary function, but consensus on when and how best to assess this is still lacking. Efforts should be made to standardize the report of preoperative and postoperative urinary function to provide higher level of evidence., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Nasal tip surgery is a crucial aspect of rhinoplasty in which suture techniques play a significant role. Early suturing techniques focused primarily on repositioning alar cartilage remnants after they had undergone significant resection. The size, contour, and orientation of the medial and lateral crura are primary factors in creating a tip shape. In this review, we retrospectively evaluated obliquely oriented dome sutures with triangular dome resection that was performed in 540 rhinoplasty cases at Yunus Emre Hospital between 2015 and 2020. Dome-defining sutures were placed, and a triangular cartilage resection was performed. Subsequently, oblique sutures were placed to achieve the desired lateral cartilage position. Objective assessment of postoperative results (Objective Rhinoplasty Outcome Score), patient satisfaction assessments, and nasal examinations were conducted. The objective assessments of the esthetic results showed a significant improvement, with a mean score of 3.6, which represents a good to excellent outcome. Most patients were subjectively satisfied with the surgical outcomes of rhinoplasty. No serious complications, such as infection, recurrence of deviation, nasal obstruction, or esthetic problems such as dorsal irregularities, were observed after surgery. Overall, suturing techniques play an important role in determining the nasal tip shape. Our technique is beneficial for maintaining a favorable lateral crural position, leading to improved patient satisfaction., Competing Interests: The authors report no conflicts of interest., (Copyright © 2023 by Mutaz B. Habal, MD.)

Abstract: Limited data are available for real-world impact of the COVID-19 pandemic on chronic pain patients. This study aimed to evaluate pain intensity, depression, and anxiety status in chronic pain patients during the COVID-19 pandemic. A total of 110 patients with chronic pain participated on a voluntary basis in this questionnaire survey. The questionnaire form elicited information on sociodemographic characteristics and prepandemic and pandemic data on analgesic need, access to medication, visual analog scale (VAS) pain, Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) scores. The COVID-19 pandemic resulted in increased levels of depression (74.5%), anxiety (66.4%), increase in analgesic need (60%), and limited access to analgesic drugs (40.0%). In conclusion, our findings revealed significant increase in VAS pain intensity, BDI, and BAI scores during the COVID-19 pandemic compared with prepandemic period among chronic pain patients, particularly for patients with increased need of analgesics during pandemic., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Purpose of Review: Coronavirus disease (COVID-19) has caused a crisis in the entire healthcare system since its emergence. The urgency and priority of various diseases have impacted the medical and surgical treatment in this period. We aim to review the impact of COVID-19 on lower urinary tract symptoms (LUTS) and management., Recent Findings: There may be a relationship between COVID-19 and de novo or increased LUTS. Patients with LUTS should also be evaluated for COVID-19. Management of diseases has varied during the COVID-19 due to the density of the pandemic. Virtual consultations can mitigate patients who are postponed or cancelled, such as patients with LUTS. Patients suffering voiding dysfunction may manage with oral medications such as alpha blocker and 5-alpha reductase inhibitor via telemedicine. Minimally invasive procedures with a low risk of complications and a short hospitalization time should be considered in complicated cases such as the inability to catheterize., Summary: Telemedicine should be implemented on managements of noncomplicated LUTS and voiding dysfunction. Each centre can schedule its LUTS management approach according to the density of pandemic. Virtual consultations need to be developed to compete with face-to-face consultations., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Objective: Dynamic thiol-disulphide homeostasis is an indicator of the antioxidant system that interacts early with the oxidative environment. This study aimed to assess the dynamic thiol/disulphide balance in individuals with white-coat hypertension (WCH)., Methods: This cross-sectional study included a total of 117 individuals who presented to our outpatient cardiology clinic. Seventy patients were diagnosed with WCH. All blood samples were obtained from the patients after a minimum of 8 h of fasting, centrifuged immediately, stored in Eppendorf tubes, and protected at -80°C., Results: The two groups were well-balanced in terms of age, gender, and BMI. Native thiol and total thiol levels were lower in the WCH group than in normotensive individuals. However, disulphide levels were higher in the former. Serum disulphide concentration positively correlated with 24-h SBP, and 24-h DBP. In backward stepwise logistic regression analysis, serum disulphide [odds ratio (OR) = 1.165 (1.089-1.245), 95% confidence interval (CI), P < 0.001] and serum total thiol levels [OR = 0.992 (0.984-1.000), 95% CI, P = 0.050] were independently associated with WCH., Conclusion: We demonstrated that dynamic thiol/disulphide balance shifted strongly towards disulphide formation due to thiol oxidation in patients with WCH., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Objective: COVID-19 is a disease with high mortality, and risk factors for worse clinical outcome have not been well-defined yet. The aim of this study is to delineate the prognostic importance of presence of concomitant cardiac injury on admission in patients with COVID-19., Methods: For this multi-center retrospective study, data of consecutive patients who were treated for COVID-19 between 20 March and 20 April 2020 were collected. Clinical characteristics, laboratory findings and outcomes data were obtained from electronic medical records. In-hospital clinical outcome was compared between patients with and without cardiac injury., Results: A total of 607 hospitalized patients with COVID-19 were included in the study; the median age was 62.5 ± 14.3 years, and 334 (55%) were male. Cardiac injury was detected in 150 (24.7%) of patients included in the study. Mortality rate was higher in patients with cardiac injury (42% vs. 8%; P < 0.01). The frequency of patients who required ICU (72% vs. 19%), who developed acute kidney injury (14% vs. 1%) and acute respiratory distress syndrome (71%vs. 18%) were also higher in patients with cardiac injury. In multivariate analysis, age, coronary artery disease (CAD), elevated CRP levels, and presence of cardiac injury [odds ratio (OR) 10.58, 95% confidence interval (CI) 2.42-46.27; P < 0.001) were found to be independent predictors of mortality. In subgroup analysis, including patients free of history of CAD, presence of cardiac injury on admission also predicted mortality (OR 2.52, 95% CI 1.17-5.45; P = 0.018)., Conclusion: Cardiac injury on admission is associated with worse clinical outcome and higher mortality risk in COVID-19 patients including patients free of previous CAD diagnosis., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)